Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 10/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SCN1A | P35498 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2059352 | 0.86 | SCN4A (0.51) | SCN4ACYP3A4KMT2ANPC1RAB9A | |
| SCHEMBL2059387 | 0.83 | KLK5 (0.39) | SCN4ACYP3A4KMT2ASCN5AHTR2B | |
| SCHEMBL2059385 | 0.83 | KLK5 (0.39) | SCN4ACYP3A4KMT2ASCN5AHTR2B | |
| SCHEMBL2058998 | 0.81 | KMT2A (0.44) | SCN4ACYP3A4CYP1A2CYP2D6NFKB1 | |
| SCHEMBL2059339 | 0.78 | SCN4A (0.33) | SCN4ACYP3A4CYP1A2CYP2D6NFKB1 | |
| SCHEMBL2059530 | 0.77 | ATM (0.46) | SCN4ACYP3A4KMT2ASCN5AHTR2B | |
| SCHEMBL2059527 | 0.77 | ATM (0.46) | SCN4ACYP3A4KMT2ASCN5AHTR2B | |
| SCHEMBL7994649 | 0.76 | CYP3A4 (0.56) | SCN4ACYP3A4CYP2D6KMT2ASCN5A | |
| SCHEMBL9951913 | 0.76 | ABCC3 (0.61) | SCN4ACYP3A4KMT2ANPC1RAB9A | |
| SCHEMBL2058967 | 0.75 | ABCC3 (0.38) | SCN4ACYP3A4KMT2ASCN5AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968707-B2 | Reacting an amino, hydroxy substituted amide with a heterocyclic substituted carboxylic acid to produce (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl) amino-3-hydroxy-5-[2S-1-imidazolidin-2-onyl)-3-methyl-butanoyl] amino-1,6-diphenylhexane; inhibitors of HIV infection | ABBOTT LABORATORIES (US) | 2011-06-28 | — | — | US | disclosed |
| US-20080139811-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBVIE INC. | 2008-06-12 | — | — | US | disclosed |
| EP-1295874-A2 | Retroviral protease inhibiting compounds | Abbott Laboratories (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6472529-B2 | VIRICIDES | ABBOTT LABORATORIES | 2002-10-29 | — | — | US | disclosed |
| EP-0882024-B1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2002-02-06 | — | — | EP | disclosed |
| US-20020004503-A1 | Retroviral protease inhibiting compounds | ABBVIE INC. | 2002-01-10 | — | — | US | disclosed |
| EP-1170289-A2 | Retroviral protease inhibiting compounds | Abbott Laboratories (US) | 2002-01-09 | — | — | EP | disclosed |
| US-6313296-B1 | 2-PYRROLIDINONE-1-ACETIC ACID DERIVATIVES; VIRICIDES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV); ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) TREATMENT | ABBOTT LABORATORIES | 2001-11-06 | — | — | US | disclosed |
| US-6284767-B1 | AIDS; MIXTURE WITH ENZYME INHIBITOR | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139811-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | SERPINB1, PREP, DNPEP | SCN4A 4599/4885CYP3A4 1729/4885CYP1A2 3416/4885 |
| US-20020004503-A1 | Retroviral protease inhibiting compounds | SERPINB1, PREP, TMPRSS15 | SCN4A 4596/4885CYP3A4 1600/4885CYP1A2 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.